Background: There is now a wealth of data supporting the use of beta-blockers in heart failure and the additional pharmacological properties of carvedilol are thought to play an important role in the therapeutic efficacy of carvedilol in this disease.
Methods and Results: Carvedilol is licensed for the treatment of essential hypertension, chronic stable angina, and mild to moderate chronic heart failure. This article provides an up-to-date review of the clinical pharmacology of carvedilol, with particular emphasis on its clinical effects in heart failure.
Conclusion: Carvedilol is a multiple-action neurohormonal antagonist that offers non selective beta-blockade, alpha-1 blockade, antioxidant, anti-ischemic mortality, and anti proliferative properties. In addition to reductions in hospitalization and mortality rates, benefits of carvedilol in heart failure include dramatic improvements in left ventricular function and other parameters of cardiac remodeling.
Bartsch W., Sponer G., Strein K., et al. Pharmacological characteristics of the stereoisomers of carvedilol . Eur J Clin Pharmacol38(Suppl 2):S 104, 1990
2.
Feuerstein GZ , Poste G., Ruffolo RRCarvedilol update III. Rationale for use in congestive heart failure. Drugs Today31:307, 1995
3.
Ruffolo RR, Boyle DA, Brooks DP, et al. Carvedilol: a novel cardiovascular drug with multiple actions . Cardiovasc Drug Rev10:127, 1992
4.
Ruffolo RRBoyle DA, Venuti RP, Lukas MAPreclinical and clinical pharmacology of carvedilol. J Hum Hypertens7(Suppl 1):2, 1993
5.
von Mollendorf E., Reiff K., Neugebauer G.Pharmacokinetics and bioavailability of carvedilol, a vasodilating beta-blocker. Eur J Clin Pharmacol33:511, 1987
6.
Abshagen U.A new molecule with vasodilating and beta-adrenoceptor blocking properties . J Cardiovasc Pharmacol10(Suppl 11):S23, 1987
7.
Neugebauer G. , Akpan W., Kaufmann B., Reiff K.Stereoselective disposition of carvedilol in man after intravenous and oral administration of the racemic compound. Eur J Clin Pharmacol38:S 108, 1990
8.
Neugebauer G. , Gabor M., Reiff K.Disposition of carvedilol enantiomers in patients with liver cirrhosis: Evidence for disappearance of stereoselective first-pass extraction. J Cardiovasc Pharmacol19:S142, 1992
9.
Neugebauer G. , Neubert P.Metabolism of carvedilol in man . Eur J Drug Metab Pharmacokinet16:148, 1991
10.
Neugebauer G., Akpan W., von Mollendorf EV, et al. Pharmacokinetics and disposition of carvedilol in humans. J Cardiovasc Pharmacol10(Suppl 11):S85, 1987
11.
Oldham HG, Clarke SEIn vitro identification of the human cytochrome P450 enzymes involved in the metabolism of R(+)- and S(—)—carvedilol. Drug Metab Dispos25:970, 1997
12.
Zhou HH, Wood Ajj.Stereoselective disposition of carvedilol is determined by CYP2D6 . Clin Pharmacol Ther57:518, 1995
13.
Varin F., Cubeddu LX, Powell JRLiquid chromatographic assay and disposition of carvedilol in healthy volunteers . J Pharm Sci75:1195, 1986
14.
Fujimaki M. , Hakusui H., Hasegawa H.Assay and disposition of carvedilol enantiomers in humans and monkeys: Evidence of stereoselective presystemic metabolism . J Pharm Sci79:568, 1990
15.
Louis WJ, McNeil JJ, Workman BS, et al. A pharmacokinetic study of carvedilol (BM 14.190) in elderly subjects: Preliminary report. J Cardiovasc Pharmacol10(Suppl): S89, 1987
16.
Neugebauer G. , Gabor M., Reiff K.Pharmacokinetics and bioavailability of carvedilol in patients with liver cirrhosis. Drugs36(Suppl 6):148,1988
17.
Kramer BK, Ress KM, Erley CM, Risler T.Pharmacokinetics and blood pressure effects of carvedilol in patients with chronic renal failure. Eur J Clin Pharmacol43:85, 1992
18.
Gehr Twb, Tenero DM, Boyle DA, et al. The pharmacokinetics of carvedilol and its metabolites after single and multiple dose oral administration in patients with hypertension and renal insufficiency. Eur J Clin Pharmacol55:269, 1999
19.
Morgan TO, Anderson A., Cripps J., Adam W.The use of carvedilol in elderly hypertensive patients. Eur J Clin Pharmacol38:S129, 1990
20.
Tenero D., Ilson B., Boyle D., et al. Dose-proportional stereoselective kinetics of carvedilol in patients with CHF. Clin Pharm Ther59:201 (Abstract PIII-54), 1996
21.
Sponer G., Bartsch W., Strein K.Pharmacological profile of carvedilol as a beta-blocking agent with vasodilating and hypotensive properties. J Cardiovasc Pharmacol9:317, 1987
22.
Bristow MR, Larrabee P., Muller-Beckmann B., et al. Effects of carvedilol on adrenergic receptor pharmacology in human ventricular myocardium and lymphocytes. Clin Investig70:S105, 1992
23.
Senior R., Muller-Beckmann B., DasGupta P., et al. Effects of carvedilol on ventricular arrhythmias. J Cardiovasc Pharmacol19(Suppl):S117, 1992
24.
Dupont AG, Van der Niepen P., Taeymans Y., et al. Effect of carvedilol on ambulatory blood pressure, renal hemodynamics and cardiac function in essential hypertension. J Cardiovasc Pharmacol10(Suppl 11):S130, 1987
25.
Nichols AJ, Gellai M., Ruffolo RRStudies on the mechanism of arterial vasodilation produced by the novel antihypertensive agent, carvedilol. Fundam Clin Pharmacol5:25, 1991
26.
Cubeddu LX, Fuenmayor N., Varin F., et al. Mechanism of the vasodilatory effect of carvedilol in normal volunteers: A comparison with labetalol. J Cardiovasc Pharmacol10 (Suppl 11):S81,1987
27.
Tomlinson B. , Cronin CJ, Graham BR, Prichard BNHemodynamics of carvedilol in normal subjects compared with propranolol, pindolol, and labetalol. J Cardiovasc Pharmacol10(Suppl 11):S69, 1987
28.
Sundberg S. , Tiihonen K., Gordin A.Vasodilatory effects of carvedilol and pindolol . J Cardiovasc Pharmacol10 (Suppl 11):S76, 1987
29.
Strein K., Sponer G.Experimental and clinical pharmacology of carvedilol and other drugs combining vasodilation and beta-adrenoceptor antagonism in a single molecule . Z Kardiol79(Suppl 3):89, 1990
30.
Franz I-W., Agrawal B., Wiewel D., Ketelhut R.Comparison of the antihypertensive effects of carvedilol and metoprolol on resting and exercise blood pressure. Clin Invest70:S53, 1992
31.
Gellai M., de Wolf R., Ruffolo RREffect of carvedilol on renal hemodynamics and renal excretory function in spontaneously hypertensive rats. Pharmacology41:200, 1990
32.
Tomita K., Makumo F.Effect of long-term carvedilol therapy on renal function in essential hypertension . J Cardiovasc Pharmacol19(Suppl):97, 1992
33.
Kohno M., Takeda T., Ishii M., et al. Therapeutic benefits and safety of carvedilol in the treatment of renal hypertension. An open short-term study. Drugs36(Suppl 6): 129,1988
34.
Masumura H. , Miki S., Kaifu Y., et al. Pharmacokinetics and efficacy of carvedilol in hypertensive patients with chronic renal failure and hemodialysis patients . J Cardiovasc Pharmacol19(Suppl 1):S102, 1992
35.
Deetjen A., Heidland A., Pangerl A., et al. Antihypertensive treatment with a vasodilating beta-blocker, carvedilol, in chronic hemodialysis patients. Clin Nephrol43:47, 1995
36.
Di Lenarda A., Gilbert EM, Olsen SLAcute hemodynamic effects of carvedilol versus metoprolol in idiopathic dilated cardiomyopathy. J Am Coll Cardiol17:142A, 1991
37.
Metra M., Nodari S., Garbellini M., et al. Effects of mid-and long-term (3-4 years) carvedilol administration in patients with idiopathic dilated cardiomyopathy. Cardiologica42:503, 1997
38.
Lowes BD, Gill EA, Abraham WT, et al. Effects of carvedilol on left ventricular mass, chamber geometry, and mitral regurgitation in chronic heart failure. Am J Cardiol83:1201, 1999
39.
Gilbert EM, Abraham WT, Olsen S., et al. Comparative hemodynamic, left ventricular functional and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation94:2817, 1996
40.
Di Lenarda A, Sabbadini G., Salvator L., et al. Long-term effects of carvedilol in idiopathic dilated cardiomyopathy with persistent left ventricular dysfunction despite chronic metoprolol. J Am Coll Cardiol33:1926, 1999
41.
Metra M., Nodari S., Garbellini M., et al. Comparative effects of metoprolol or carvedilol on resting and peak exercise hemodynamics and functional capacity in patients with chronic heart failure. Circulation96:I-577-I-578 (Abstract), 1997
42.
Abraham WT, Tsvetkova T., Lowes BD, et al. Carvedilol improves renal hemodynamics in patients with chronic heart failure. Circulation98(Suppl):I-378 (Abstract), 1998
43.
Feuerstein G., Yue T-L, Ma XL, Ruffolo R. Carvedilol: A novel multiple action antihypertensive drug that provides major organ protection . Cardiovasc Drug Rev12:85, 1994
44.
Feuerstein GZ, Shustermen NH, Ruffolo RRCarvedilol update IV: Prevention of oxidative stress, cardiac remodeling and progression of congestive heart failure. Drugs Today33:453,1997
45.
Migliavacca E., Ancerewicz J., Carrupt PATheoretical parameters to characterize antioxidants Part 2: The cases of melatonin and carvedilol . Helvetica Chimica Acta81: 1337,1998
46.
Maggi E., Marchesi E., Covini D., et al. Protective effects of carvedilol, a vasodilating beta-adrenoceptor blocker, against in vivo low density lipoprotein oxidation in essential hypertension . J Cardiovasc Pharmacol27:532, 1996
47.
Kukin ML, Kalman J., Charney RH, et al. Prospective, randomised comparison of effect of long-term treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction and oxidative stress in heart failure. Circulation99:2645, 1999
48.
Giugliano D. , Acampora R., Marfella R., et al. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension: A randomized, control trial. Ann Intern Med126:955, 1997
49.
Marchi F., Ciriello G.Efficacy of carvedilol in mild to moderate essential hypertension and effects on microalbuminuria: A multicenter, randomized, pen-label, controlled study versus atenolol. Adv Ther12:212, 1995
50.
Agrawal B., Wolf K., Berger A., Luft FCEffect of antihypertensive treatment on qualitative estimates of microalbuminuria . J Hum Hypertens10:551, 1996
51.
Agnoletti L. , Comini L., Bachetti T.Effects of carvedilol on TNF-alpha-induced apoptosis in human endothelial cells. J Mol Cell Cardiol30:A30, 1998 (abstract)
52.
Belch Jjf, Bridges AB, Scott N., Chapra M.Oxygen free radicals and congestive heart failure. Br Heart J65:245, 1991
53.
McMurray J. , Chopra M., Abdullah I., et al. Evidence of oxidative stress in chronic heart failure in humans. Eur Heart J14:1493, 1993
Magnani B., Rapezzi C., Galie N., Ortolani P.Use of multiple-action agents on the heart: Pathophysiological and therapeutic considerations. J Cardiovasc Pharmacol19(Suppl 1): S44,1992
56.
Louis WJ, Krum H., Conway E.A risk-benefit assessment of carvedilol in the treatment of cardiovascular disorders. Drug Saf11:86,1994
57.
Seguchi H., Nakamura H., Aosaki N., et al. Effects of carvedilol on serum lipids in hypertensive and normotensive subjects. Eur J Clin Pharmacol38(Suppl 2):139, 1990
58.
Schnurr E., Widmann L., Glocke M.Efficacy and safety of carvedilol in the treatment of hypertension . J Cardiovasc Pharmacol10(Suppl 11):S101, 1987
59.
Hauf-Zachariou U., Widmann L., Zulschorf B., et al. A double blind comparison of the effects of carvedilol and captopril on serum lipid concentrations in patients with mild to moderate essential hypertension and dyslipidaemia . Eur J Clin Pharmacol45:95, 1993
60.
Jacob S., Rett K., Wicklmayr M., et al. Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: The carvedilol-metoprolol study. J Hypertens14:489, 1996
61.
Albergati F. , Paterno E., Venuti RP, et al. Comparison of the effects of carvedilol and nifedipine in patients with essential hypertension and non-insulin-dependent diabetes mellitus. J Cardiovasc Pharmacol19(Suppl 1):S86, 1992
62.
Waagstein F. , Hjalmarson A., Swedberg K., Wallentin L.Beta blockers in dilated cardiomyopathy: They work. Eur Heart J4:173, 1983
63.
Waagstein F. , Bristow MR, Swedberg K., et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet342:1441, 1993
64.
Engelmeier RS, O'Connell JB, Walsh R., et al. Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy: A double-blind, randomized, placebo controlled trial. Circulation72:536, 1985
65.
Anderson JL , Lutz JR, Gilbert EM, et al. A randomized trial of low-dose beta-blockade therapy for idiopathic dilated cardiomyopathy. Am J Cardiol55:471, 1985
66.
Gilbert EM, Anderson JL, Deitchman D., et al. Long-term beta-blocker vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy: A double-blind, randomized study of bucindolol versus placebo. Am J Med88:223, 1990
67.
Woodley SL, Gilbert EM, Anderson JL, et al. Beta-blockade with bucindolol in heart failure caused by ischemic versus idiopathic dilated cardiomyopathy. Circulation84:2426, 1991
68.
Bristow MR, O'Connell JB, Gilbert EM, et al. Dose-response of chronic beta-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Circulation89:1632, 1994
69.
Bristow MR, Ginsburg R., Umans V., et al. Beta-1 and beta-2 adrenergic receptor subpopulations in nonfailing and failing ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1 receptor down-regulation in heart failure. Circ Res59:297, 1986
70.
Olsen SL, Gilbert EM, Renlund DG, et al. Carvedilol improves symptoms and left ventricular function and symptoms in chronic heart failure: a double-blind, randomized study. J Am Coll Cardiol25:1225, 1995
71.
Krum H., Sackner-Bernstein JD, Goldsmith RL, ct al.Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure. Circulation92:1499, 1995
72.
Metra M., Nardi M., Giubbini R, DeiCas L. Effects of short- and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic cardiomyopathy. J Am Coll Cardiol24:1678, 1994
73.
Gilbert EM, Olsen SL, Renlund DB, Bristow MRBeta-adrenergic receptor regulation and left ventricular function in idiopathic dilated cardiomyopathy. Am J Cardiol71:23C, 1993
Australia-New Zealand Heart Failure Research Collaborative Group.Effects of carvedilol, a vasodilator-beta-blocker, in patients with congestive heart failure due to ischemic heart disease. Circulation92:212, 1995
76.
Packer M., Colucci WS, Sackner-Bernstein JD, et al. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure: The PRECISE trial. Circulation11:2793,1996
77.
Bristow MR, Gilbert EM, Abraham WT, et al. Multicenter oral carvedilol heart failure assessment (MOCHA): A six-month dose-response evaluation in class II-IV patients. Circulation92(Suppl 1):1142,1995
78.
Colucci WS, Packer M., Bristow MR, et al. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation94:2800, 1996
79.
Cohn JN, Fowler MB, Bristow MR, et al. Safety and efficacy of carvedilol in severe heart failure. J Card Fail3:173,1997
80.
De May C., Brendel E., Enterling D.Carvedilol increases the systemic bioavailability of oral digoxin . Br J Clin Pharmacol29:486,1990
81.
Eichhorn EJ, Lukas MA, Wu B., et al. Effect of concomitant digoxin and carvedilol therapy of mortality and morbidity. Eur Heart J19(Abstract Suppl):301 (Abstract P1695),1998
82.
Jutmann JR, de Vries Robles P., Venuti RPSafety of the coadministration of carvedilol and nifedipine sustained-release in the treatment of essential hypertension. J Cardiovasc Pharmacol19(Suppl 1):S134, 1992
83.
Widmann L., van der Does R., Horrmann M., Machwirth M.Safety and antihypertensive efficacy of carvedilol and atenolol alone and in combination with hydrochlorothiazide. Eur J Clin Pharmacol38:S143, 1990
84.
Dupont AG, Schoors DF, Venuti RPThe safety of adding carvedilol to hypertensive patients inadequately treated with diuretics. Eur J Clin Pharmacol38:S153, 1990
85.
Luzier AB, Kazierad DJEffect of carvedilol on the anticoagulant effect of warfarin and on the pharmacokinetics of warfarin enantiomers. Pharmacotherapy15:363, 1995
86.
Krum H., Shusterman N., MacMahon S., Sharpe N.Safety of carvedilol in patients with chronic heart failure receiving concomitant amiodarone therapy. Circulation96:I-578, 1997
